within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J02A_AntimycoticsForSystemicUse.J02AX01_Flucytosine;

model Flucytosine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 1.7500000000000002e-06,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0006,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0115,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Flucytosine</td></tr><tr><td>ATC code:</td><td>J02AX01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.5</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Flucytosine is an antifungal medication used primarily in combination with other agents (commonly amphotericin B) for the treatment of severe systemic fungal infections such as cryptococcal meningitis and candidiasis. It acts as a pyrimidine analog, interfering with fungal DNA and RNA synthesis. Flucytosine is approved by regulatory agencies and remains in use today, mainly for specific difficult-to-treat infections and susceptible organisms.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data for orally administered flucytosine in adult patients with normal renal function.</p><h4>References</h4><ol><li><p>Kim, HY, et al., &amp; Alffenaar, JW (2020). Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. <i>Frontiers in pharmacology</i> 11 894–None. DOI:<a href=\"https://doi.org/10.3389/fphar.2020.00894\">10.3389/fphar.2020.00894</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32595511/\">https://pubmed.ncbi.nlm.nih.gov/32595511</a></p></li><li><p>Dupont, B (2001). [Choice and use of antifungal drugs]. <i>La Revue du praticien</i> 51(7) 752–757. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11387672/\">https://pubmed.ncbi.nlm.nih.gov/11387672</a></p></li><li><p>Hayashi, Y, et al., &amp; Yamada, Y (1995). [Study of serial bronchoalveolar lavage in patients with aspergilloma: cell reaction at the affected sites and penetration of miconazole and flucytosine into the lesion]. <i>Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases</i> 69(5) 517–523. DOI:<a href=\"https://doi.org/10.11150/kansenshogakuzasshi1970.69.517\">10.11150/kansenshogakuzasshi1970.69.517</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7602184/\">https://pubmed.ncbi.nlm.nih.gov/7602184</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J02AX01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Flucytosine;
